儿童多发性硬化换用口服或输注DMT的真实世界疗效
本研究基于美国儿童MS中心网络2615例儿童起病脱髓鞘病患者,分析212例初始平台注射剂治疗后换用不同DMT的MS/CIS患儿的复发率。换用口服或输注DMT者复发率显著低于换用另一种注射剂者(率比分别为0.38和0.21),提示换用口服或输注DMT疾病控制更佳。
要点
- 儿童MS换用口服DMT较换用注射剂显著降低复发率(率比0.38)。
- 换用输注DMT较换用注射剂复发率更低(率比0.21)。
- 换用输注DMT者基线增强病灶比例更高(67%),提示选择偏倚可能。
核心结论
- 儿童MS/CIS患者从平台注射剂换用口服或输注DMT,相比换用另一种注射剂,疾病控制更佳。
研究设计与样本
- 回顾性队列研究,来自美国12家儿童MS中心,纳入2615例儿童起病脱髓鞘病患者,其中212例在18岁前换用DMT并纳入分析。
主要发现
- 换用口服DMT者年化复发率(ARR)为0.34(95%CI 0.20-0.57),换用输注DMT者为0.18(95%CI 0.09-0.37),换用注射剂者为0.88(95%CI 0.52-1.48)。
- 与换用注射剂相比,换用口服DMT的复发率比为0.38(95%CI 0.21-0.69),换用输注DMT的率比为0.21(95%CI 0.10-0.44),p<0.001。
- 调整后人年需治疗人数:口服较注射剂预防1次复发为1.84(95%CI 1.03-8.69),输注较注射剂为1.43(95%CI 1.00-3.88)。
- 换用口服或输注DMT者发病年龄和换药年龄更大,换用输注DMT者增强病灶比例更高(注射剂45%、口服28%、输注67%)。
临床怎么用
- 对于初始平台注射剂治疗控制不佳的儿童MS患者,换用口服或输注DMT可能优于换用另一种注射剂。
- 选择换用方案时需考虑患者年龄、疾病活动性(如增强病灶)及长期安全性数据缺乏的问题。
局限性
- 研究为回顾性设计,可能存在选择偏倚(如换用输注DMT者基线增强病灶更多)。
- 样本量较小(212例),需长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. METHODS: Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. RESULTS: A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88). INTERPRETATION: Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2026;99:715-729.
引用
- Abrams AW, Waltz M, Casper TC, et al. Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis. Ann Neurol. 2025. PMID: 41195640. doi:10.1002/ana.78086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。